COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Afatinib in Advanced NRG1-Rearranged Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04410653
Recruitment Status : Not yet recruiting
First Posted : June 1, 2020
Last Update Posted : June 1, 2020
German Consortium for Translational Cancer Research
Information provided by (Responsible Party):
German Cancer Research Center

Tracking Information
First Submitted Date  ICMJE May 15, 2020
First Posted Date  ICMJE June 1, 2020
Last Update Posted Date June 1, 2020
Estimated Study Start Date  ICMJE September 1, 2020
Estimated Primary Completion Date July 1, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 29, 2020)
Disease Control Rate [ Time Frame: 6 months ]
Primary objective of the study is to assess clinical activity of afatinib in adult patients with (locally) advanced or recurrent solid tumors harboring NRG1-rearrangments. Clinical efficacy is determined by disease control rate (DCR) including CR, PR, and SD according to RECIST v1.1 criteria.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: May 29, 2020)
  • Progression-free Survival [ Time Frame: through study completion, an average of 1 year ]
    To assess progression-free survival (PFS) of afatinib in adult patients with advanced solid tumors harboring NRG1-rearrangments.
  • Overall survival [ Time Frame: through study completion, an average of 1 year ]
    To assess OS (overall survival) of afatinib in adult patients with advanced solid tumors harboring NRG1-rearrangments.
  • Safety and Tolerability: Toxic effects are graded according to the National Cancer Institute Common Toxicity Criteria (CTCAE) version 5.0 [ Time Frame: 6 months ]
    This endpoint includes all AEs, their severity, SAEs, the relation of AEs to the study treatment, dose modifications for toxicity and discontinuation of study treatment during the trial phase. Toxic effects are graded according to the National Cancer Institute Common Toxicity Criteria (CTCAE) version 5.0.
  • Patient reported Outcomes [ Time Frame: 6 months ]
    Patient Reported Outcomes including quality of life (QLQ) of patients treated with afatinib. Patient-Reported Outcomes (PROs) including health-related quality of life (QoL) are calculated as the new European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Summary Score recommended by the EORTC Quality of Life Group. In addition, the EORTC QLQ function and symptom scores will be calculated according to the actual EORTC Scoring Manual.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Afatinib in Advanced NRG1-Rearranged Malignancies
Official Title  ICMJE Afatinib in Advanced NRG1-Rearranged Malignancies: the NCT/DKTK PMO-1604 Phase-II Trial
Brief Summary

Whole-genome and transcriptome sequencing of patients with advanced solid tumors enrolled in the NCT/DKTK MASTER (Molecularly Aided Stratification for Tumor Eradication Research) program revealed recurrent NRG1 fusions in a substantial proportion of patients with KRAS wild-type (KRASwt) pancreatic adenocarcinoma (PDAC) and a case of signet-ring cell carcinoma of the appendix. NRG1 rearrangements drive tumor development through ERBB receptor-mediated signaling, as evidenced by objective response to ERBB inhibition in two cases of NRG1-rearranged PDAC in the MASTER cohort. Recently, NRG1 fusions have also been identified as a therapeutic target in a substantial number of the invasive mucinous subtype of lung adenocarcinoma (IMA) as well as in cholangiocellular carcinoma and, at low incidence, other tumor entities, suggesting oncogenic properties across a broader spectrum of malignancies.

Within this phase II clinical trial, the investigators aim to investigate the efficacy of the pan-ERBB inhibitor afatinib in advanced-stage NRG1-rearranged malignancies across all tumor entities following progression on standard therapy. Due to the enrichment of NRG1-rearrangements observed in KRASwt PDAC and IMA, two separate study arms will focus on these tumor entities while a third arm will allow inclusion of patients with any other NRG1 rearranged malignancy. Recruitment of adequate patient numbers in this well-defined molecular subgroup will be achieved by a multicenter approach including all DKTK partner sites and on-site pre-screening of PDAC for KRAS mutational status. Eligible patients will be identified by in-depth molecular characterization of tumors within the NCT/DKTK MASTER program or identification of a NRG1-rearranged tumor by another method for fusion detection (e.g. gene fusion panel).

Patients with NRG1-rearranged tumors fulfilling eligibility criteria will be offered to participate in the trial and receive afatinib monotherapy until tumor progression or discontinuation for other reasons. To assess mechanisms of secondary resistance and to investigate the clinical impact of liquid biopsies in this setting, blood samples for exome sequencing will be taken prior to initiation of the study treatment as well as at the time of progression.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic and Locally Advanced NRG1-rearranged Malignancies
Intervention  ICMJE Drug: Afatinib 40 MG
single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events
Study Arms  ICMJE
  • Experimental: Arm 1 (KRASwt PDAC)
    Intervention: Drug: Afatinib 40 MG
  • Experimental: Arm 2 (IMA)
    Intervention: Drug: Afatinib 40 MG
  • Experimental: Arm 3 (other)
    Intervention: Drug: Afatinib 40 MG
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: May 29, 2020)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 1, 2023
Estimated Primary Completion Date July 1, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Provision of a written informed consent
  2. Patient is able to understand and comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations
  3. Progressive metastatic or locally advanced NRG1-Rearranged Malignancy as determined by investigator
  4. At least one measurable lesion that can be accurately assessed at baseline by CT or MRI and is suitable for repeated assessment
  5. Prior administration of at least one standard treatment for primary and/or relapsed malignancy according to current guidelines
  6. Eastern Cooperative Oncology Group Performance Status ≤ 1
  7. Male or female patient aged ≥ 18, no upper age limit
  8. Postmenopausal or evidence of non-childbearing status. For women of childbearing potential: negative urine pregnancy test at baseline and highly effective forms of contraception in place thereafter as well as confirmed negative urine pregnancy test prior to treatment on day 1 of every cycle and at end of treatment period.

    Evidence of childbearing potential is defined as:

    o Fertile, following menarche and until becoming post-menopausal unless permanently sterile

    Postmenopausal or evidence of non-childbearing status is defined as:

    1. Amenorrheic for 1 year or more without an alternative medical cause following cessation of exogenous hormonal treatments PLUS Follicle stimulating hormone (FSH) levels in the postmenopausal range in women not using hormonal contraception or hormonal replacement therapy
    2. Surgical sterilisation (bilateral oophorectomy, hysterectomy or bilateral salpingectomy)
  9. Female patients of child bearing potential and male patients with partners of child bearing potential, who are sexually active, must agree to the use of two highly effective forms of contraception. This should be started from the signing of the informed consent and continue throughout period of taking study treatment and for 1 month (female patients) / 3 months (male patients) after last dose of study drug.
  10. Identification of NRG1 rearrangements within NCT/DKTK MASTER (Heidelberg Ethics Committee Reference No.: S-206/2011) or identification of a NRG1 fusion by another method for fusion detection (e.g. gene fusion panel)
  11. Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment:

    1. Absolute neutrophil count (ANC) ≥1500 / mm3. (ANC >1000/mm3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor).
    2. Platelet count ≥75,000 / mm3.
    3. Estimated creatinine clearance > 45ml / min (according to Crockroft-Gault-formula).
    4. Total Bilirubin ≤ 1.5 times upper limit of normal (Patients with Gilbert's syndrome total bilirubin must be ≤4 times institutional upper limit of normal (ULN)).
    5. Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤ three times the ULN (if related to liver metastases ≤ five times ULN).
  12. Left ventricular function with resting ejection fraction ≥ 50% or above the LLN.
  13. Recovered from any previous therapy related toxicity to ≤Grade 1 at study entry (except for stable sensory neuropathy ≤Grade 2 and alopecia)
  14. Written informed consent that is consistent with ICH-GCP guidelines

Exclusion Criteria:

  1. Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years
  2. Concurrent or previous treatment within 4 weeks in another interventional clinical trial with an investigational anticancer therapy
  3. Prior treatment with afatinib
  4. Hormonal treatment within 2 weeks prior to start of study treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted)
  5. Radiotherapy within 4 weeks prior to randomization , except as follows:

    i.) Palliative radiation to target organs may be allowed up to 2 weeks prior to randomisation, and

    ii.) Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with coordinating investigator/ scientific investigator prior to enrolling.

  6. Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
  7. Known hypersensitivity to afatinib or the excipients of any of the trial drugs
  8. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of ≥ 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to randomisation.
  9. Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly prior to study entry, for the duration of study participation and for 1 month (female patients)/ 3 months (male patients) after last dose of study drug (after EOT).
  10. Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  11. Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
  12. Known pre-existing interstitial lung disease (ILD)
  13. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhoea, malabsorption)
  14. Leptomeningeal carcinomatosis
  15. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids, anti-convulsants or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment.
  16. Persistent toxicity (≥Grade 2 according to Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) caused by previous cancer therapy, excluding alopecia
  17. Clinical signs of active infection (>Grade 2 according to CTCAE version 5.0)
  18. History of HIV infection and immunocompromised patients
  19. Viral active or chronic hepatitis (HBV or HCV)
  20. Dementia or significant impairment of cognitive state
  21. Epilepsy requiring pharmacologic treatment
  22. Heart failure NYHA III/IV
  23. Severe obstructive or restrictive ventilation disorder
  24. Concomitant use of P-gp- inhibitors (e.g. ritonavir, ciclosporin A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, amiodarone) and BCRP inhibitors (e.g. rosuvastatin, sulfasalazine). The required washout period prior to starting afatinib is at least five half-lifes.
  25. Concomitant use of P-gp-inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's wort) The required washout period prior to starting afatinib is at least five half-lifes (e.g. 5 weeks for phenobarbital).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Christoph Christoph, Dr. +49 (0)351 458 ext 5532
Contact: Richard F. Schlenk, Prof. Dr. +49 (0)6221 56 ext 6228
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT04410653
Other Study ID Numbers  ICMJE NCT/DKTK PMO-1604
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Responsible Party German Cancer Research Center
Study Sponsor  ICMJE German Cancer Research Center
Collaborators  ICMJE German Consortium for Translational Cancer Research
Investigators  ICMJE
Principal Investigator: Christoph Christoph, Dr. National Center of Tumor Diseases (NCT) Dresden
PRS Account German Cancer Research Center
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP